Profiling of transmission-blocking compounds for Malaria treatment

Status
Completed
Start date
End date
Start stage
Preclinical development
End stage
Preclinical development
Disease
Malaria
Research areas
Drug

A promising series of antimalarial compounds developed in Dr. Van Voorhis’ laboratory, termed bumped kinase inhibitors (BKIs), blocks transmission of malaria parasites from infected humans to mosquitos. BVGH connected Dr. Van Voorhis with scientists at GSK’s Malaria Discovery Performance Unit (DPU) in Tres Cantos, Spain, who re-profiled several BKIs through a battery of kinase/kinome tests to characterize their safety and activity.